What is Genuity Science?
Headquartered in Ireland, Genuity Science operates at the intersection of biotechnology and data science. The company provides a comprehensive suite of services, including biobanking, nucleic acid extraction, and high-throughput next-generation sequencing. By integrating methylation profiling and rigorous quality control protocols, Genuity Science enables pharmaceutical and academic partners to accelerate precision medicine initiatives. Their market position is defined by a robust technical infrastructure that bridges the gap between raw biological samples and actionable genomic insights, effectively serving as a critical node in the modern drug discovery ecosystem.
How much funding has Genuity Science raised?
Genuity Science has raised a total of $620M across 4 funding rounds:
Series A
$15M
Series B
$165M
Unspecified
$240M
Series C
$200M
Series A (2013): $15M with participation from Polaris Partners and ARCH Venture Partners
Series B (2017): $165M led by Temasek, Sequoia China, Amgen Business Development, Yunfeng Capital, and 3W Partners
Unspecified (2017): $240M supported by Steamboat Ventures, Yunfeng Capital, Temasek, and 3W Partners
Series C (2018): $200M featuring Ireland Strategic Investment Fund, Steamboat Ventures, Temasek, and Yunfeng Capital
Key Investors in Genuity Science
Temasek
A global investment company headquartered in Singapore with a diversified portfolio focusing on long-term value creation across life sciences and technology sectors.
Yunfeng Capital
A prominent private equity firm that targets high-growth enterprises, often providing strategic guidance and capital to companies scaling within the Asian and international markets.
Steamboat Ventures
A venture capital firm known for its focus on early-to-growth stage technology and media investments, often leveraging deep industry expertise to support portfolio expansion.
What's next for Genuity Science?
With the recent influx of capital, Genuity Science is well-positioned to expand its operational footprint and enhance its proprietary data analytics capabilities. The company is expected to focus on scaling its sequencing throughput and deepening its integration with global clinical research networks. As the demand for high-fidelity genomic data continues to rise, Genuity Science's strategic roadmap likely involves further investment in automation and AI-driven bioinformatics to maintain its competitive edge. This phase of growth will be instrumental in transitioning the firm from a specialized service provider to a foundational partner in large-scale population health studies and personalized therapeutic development.
See full Genuity Science company page
